CAR-T Cell Therapy in China: Cost, Hospitals & Access for Foreign Patients (2026)

CAR-T cell therapy is one of the most significant breakthroughs in cancer treatment of the past decade. For patients with certain blood cancers, it has produced remission rates that were unimaginable just a few years ago. The challenge — for most patients outside the United States — has been the staggering cost: $400,000 to $600,000 per treatment in the US, before hospitalization and supportive care.

China has changed that equation. With domestically developed and FDA-equivalent approved CAR-T products, world-class oncology centers, and treatment costs of $40,000–$80,000, China is now a serious option for international patients who cannot afford or access CAR-T therapy at home. This guide explains what CAR-T is, what's available in China, how much it costs, and how foreign patients can access it.

What Is CAR-T Cell Therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a form of personalized immunotherapy where your own immune cells (T-cells) are extracted, genetically engineered in a laboratory to recognize and attack cancer cells, then infused back into your body.

Unlike chemotherapy, which attacks all rapidly dividing cells, CAR-T therapy is targeted: the engineered T-cells seek out specific proteins on cancer cell surfaces and destroy them. For eligible patients, a single infusion can produce durable remissions — including complete remissions in cancers that had relapsed after multiple treatment rounds.

Which Cancers Is CAR-T Used For?

• Diffuse large B-cell lymphoma (DLBCL) — the most common approved indication globally
• Follicular lymphoma
• Mantle cell lymphoma
• Multiple myeloma
• Acute lymphoblastic leukemia (ALL) — especially in children and young adults
• Chronic lymphocytic leukemia (CLL) — in certain clinical trial settings

Research is also ongoing for solid tumors, including lung cancer, gastric cancer, and liver cancer — areas where China's CAR-T research pipeline is particularly active.

China's Approved CAR-T Products

China's National Medical Products Administration (NMPA) — the equivalent of the US FDA — has approved several CAR-T products as of 2026. These represent both domestic innovations and licensed products.

Axicabtagene Ciloleucel (Axi-cel) — Fosun Kite

A licensed version of Yescarta (developed by Kite Pharma/Gilead), produced in China by Fosun Kite. Approved for relapsed/refractory large B-cell lymphoma. This is the most widely used CAR-T product in Chinese hospitals.

Relmacabtagene Autoleucel (Relma-cel) — JW Therapeutics

China's first domestically approved CAR-T product, developed by JW Therapeutics (a joint venture with Juno Therapeutics). Licensed for relapsed or refractory large B-cell lymphoma after two or more lines of therapy.

BCMA-Targeting CAR-T for Multiple Myeloma

Several BCMA-directed CAR-T products targeting multiple myeloma have received conditional approval or are in late-stage clinical trials in China, including products from IASO Bio and Legend Biotech (whose ciltacabtagene autoleucel is also approved in the US as Carvykti).

Clinical Trial Access

Beyond approved products, China has one of the world's most active CAR-T clinical trial pipelines — over 400 active trials as of 2025. Foreign patients may be eligible for some trials, particularly at leading cancer centers, opening access to next-generation CAR-T constructs not yet widely available anywhere.

CAR-T Therapy Cost in China vs. the United States

The cost comparison is the most compelling reason international patients look to China:

• United States: $400,000–$600,000 (product cost only); total treatment episode often exceeds $800,000
• European Union: €300,000–€450,000 where available; coverage varies significantly by country
• China: $40,000–$80,000 for the CAR-T product; total treatment episode (including hospitalization, lymphodepletion, monitoring) typically $60,000–$120,000

The tenfold cost difference stems from lower manufacturing costs, government pricing oversight, and a competitive domestic biotech market. Quality of the therapy itself is not compromised — China's CAR-T manufacturers follow GMP (Good Manufacturing Practice) standards equivalent to international benchmarks.

Top Hospitals for CAR-T Therapy in China

CAR-T therapy requires specialized infrastructure — apheresis centers for cell collection, certified clean-room manufacturing or coordination with manufacturers, and experienced hematology/oncology teams for managing cytokine release syndrome (CRS) and other side effects. These hospitals are leaders in the field:

Beijing Boren Hospital

One of China's most experienced CAR-T centers, with an international patient department and a high volume of CAR-T procedures. Has treated foreign patients from Southeast Asia, the Middle East, and Europe.

Peking University People's Hospital (Beijing)

A top public teaching hospital with a strong hematology department and active CAR-T clinical programs across multiple cancer types.

Ruijin Hospital, Shanghai Jiao Tong University

Renowned for hematological malignancies, Ruijin's CAR-T program has treated hundreds of patients and maintains strong links with domestic CAR-T manufacturers.

Tongji Hospital, Wuhan

A major national cancer center with an internationally recognized CAR-T research and treatment program, particularly strong in leukemia and lymphoma.

The First Affiliated Hospital of Zhejiang University (FAHZU)

Known for innovation and research, FAHZU has one of the most active CAR-T clinical trial programs in China, offering access to novel constructs alongside approved therapies.

Eligibility: Can Foreign Patients Access CAR-T in China?

Yes — but eligibility depends on medical and logistical factors. Here is what hospitals typically require:

Medical Criteria

• Confirmed diagnosis of a CAR-T-eligible cancer (typically relapsed/refractory after 2+ prior treatment lines)
• Adequate organ function (kidney, liver, heart, lungs) to tolerate lymphodepletion chemotherapy
• ECOG performance status of 0–2 (a measure of functional capacity)
• No active uncontrolled infection
• Sufficient T-cell counts for successful apheresis (cell collection)

Practical Requirements

• All prior medical records translated into English or Chinese
• Pathology reports and genetic/molecular testing results
• Medical visa (S2) — see our S2 Visa Guide for details
• Family member or caregiver accompaniment strongly recommended (treatment requires a minimum 4–6 week hospital stay)
• Financial confirmation prior to starting the treatment process

The CAR-T Treatment Timeline for International Patients

Understanding the timeline helps patients and families plan appropriately. CAR-T is not a day procedure — it requires an extended commitment.

1. Remote medical review (1–2 weeks): Hospital oncologists review your records and confirm eligibility before you travel
2. Arrival and pre-treatment workup (1–2 weeks): Comprehensive assessment, scans, labs, informed consent
3. Apheresis — T-cell collection (1 day): Your T-cells are collected via a blood-filtering procedure (similar to dialysis)
4. Cell manufacturing (2–4 weeks): Your T-cells are genetically modified in a certified facility; you may wait in China or return home during this period depending on the product
5. Lymphodepletion chemotherapy (3–5 days inpatient): A short course of chemotherapy to prepare your immune system
6. CAR-T infusion (1 day): The engineered cells are infused intravenously
7. Monitoring and recovery (2–4 weeks inpatient): Close monitoring for cytokine release syndrome and neurotoxicity
8. Response assessment and follow-up: Scans and labs to evaluate remission; follow-up can often be continued with your oncologist at home

Taking the Next Step

For patients with relapsed or refractory blood cancers, CAR-T therapy in China represents a potentially life-saving option that is financially accessible to many who would otherwise be priced out of treatment. With approved products, experienced centers, and an established pathway for international patients, China's CAR-T ecosystem is genuinely world-class.